The estimated Net Worth of Anthony P Iii Bihl is at least $2.24 Million dollars as of 17 May 2022. Mr. Bihl owns over 20,000 units of Meridian Bioscience stock worth over $2,242,020 and over the last 9 years he sold VIVO stock worth over $0. In addition, he makes $0 as Independent Director at Meridian Bioscience.
Sign up
Mr. Bihl VIVO stock SEC Form 4 insiders trading
Anthony has made over 21 trades of the Meridian Bioscience stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 20,000 units of VIVO stock worth $58,000 on 17 May 2022.
The largest trade he's ever made was buying 20,000 units of Meridian Bioscience stock on 17 May 2022 worth over $58,000. On average, Anthony trades about 3,160 units every 69 days since 2016. As of 17 May 2022 he still owns at least 66,000 units of Meridian Bioscience stock.
You can see the complete history of Mr. Bihl stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Anthony Bihl biography
Anthony P. Bihl III serves as Independent Director of the Company. Mr. Bihl had been Chief Executive Officer and a member of the board of managers of Bioventus, LLC, a company that develops, manufactures and sells products that promote active orthopedic healing, from December 2013 to April 2020. From June 2011 through June 2012, he was Group President American Medical Systems, or AMS, a subsidiary of Endo Pharmaceuticals. Mr. Bihl was President, Chief Executive Officer and a director of AMS from April 2008 until Endo acquired AMS in June 2011. He served as Chief Executive Officer of the Diagnostics Division of Siemens Medical Solutions from January to November 2007, and as President of the Diagnostics Division of Bayer HealthCare from 2004 through 2006. Prior to that, Mr. Bihl served in a number of operations and finance roles at Bayer HealthCare and for over 20 years at E.I. DuPont. Mr. Bihl is a director and chairman of the board of Spectral Medical, Inc. (TSX: EDTXF), a Canadian company that develops products for the diagnosis and treatment of severe sepsis and septic shock. Mr. Bihl served as a member of the Board of Directors of Nuvectra Corporation (OTC: NVTRQ) from March 2016 to May 2020. Prior to March 2016 Mr. Bihl served on the Board of Directors of Integer Holdings Corporation (NYSE: ITGR) before it spun off Nuvectra. The Board believes that Mr. Bihl is well qualified to serve on Meridian’s Board due to his 30 years of experience in the medical device industry in operations, finance and general management roles.
What's Anthony Bihl's mailing address?
Anthony's mailing address filed with the SEC is C/O SONENDO, INC., 26061 MERIT CIRCLE, SUITE 102, LAGUNA HILLS, CA, 92653.
Insiders trading at Meridian Bioscience
Over the last 22 years, insiders at Meridian Bioscience have traded over $8,089,514 worth of Meridian Bioscience stock and bought 228,244 units worth $3,053,655 . The most active insiders traders include Richard Eberly, John P. Kenny und John A Kraeutler. On average, Meridian Bioscience executives and independent directors trade stock every 41 days with the average trade being worth of $424,761. The most recent stock trade was executed by James M. Anderson on 6 January 2023, trading 8,500 units of VIVO stock currently worth $173,230.
What does Meridian Bioscience do?
Meridian Bioscience Inc. is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products.The company is dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, Meridian provides critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, Meridian provides diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. The company builds relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
What does Meridian Bioscience's logo look like?
Complete history of Mr. Bihl stock trades at Meridian Bioscience und Sonendo
Meridian Bioscience executives and stock owners
Meridian Bioscience executives and other stock owners filed with the SEC include:
-
John P. Kenny,
Pres, CEO & Director -
John Kenny,
Chief Executive Officer, Director -
Lourdes Weltzien,
Executive Vice President - Life Science -
Dr. Lourdes G. Weltzien Ph.D.,
Exec. VP of Life Science Bus. Unit -
Tony Serafini-Lamanna,
Exec. VP of Diagnostics -
Bryan Baldasare,
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Corporate Controller, Treasurer -
David Phillips,
Independent Chairman of the Board -
James Anderson,
Independent Director -
Dwight Ellingwood,
Independent Director -
Felicia Williams,
Independent Director -
Catherine Sazdanoff,
Independent Director -
John Rice,
Independent Director -
John McIlwraith,
Independent Director -
Anthony Bihl,
Independent Director -
Melissa A. Lueke,
Consultant -
Susan D. Rolih,
Consultant -
Melissa J. McCarey,
VP of Global HR -
Charles Wood,
VP of Investor Relations -
Jeff Pinkston,
Director of Corp. Fin. -
Julie Smith,
Sr. VP, Controller & Principal Accounting Officer -
Michael C. Shaughnessy,
EVP, Pres Meridian Global Dx -
Amy Winslow,
EVP, Pres & CEO of Magellan -
Melissa Lueke,
Exec VP, CFO -
Marco G. Calzavara,
Pres & Managing Director, MBE -
Vecheslav A Elagin,
Sr VP, Research & Development -
Eric S. Rasmussen,
EVP, Bus. Development/Strategy -
Kenneth Kozak,
Vice President -
Susan Rolih,
EVP, Reg & Quality Systems -
Lawrence Baldini,
VP, Operations -
Robert J Ready,
Director -
Marviette D. Johnson,
VP, Human Resources -
Todd W Motto,
VP, Sales and Marketing -
Grady Barnes,
VP, Research & Development -
Gregory S Ballish,
VP, Sales and Marketing -
James Buzard,
Director -
Richard Eberly,
Ex. VP, Gen Mgr. Mer. Life Sci -
Gary P Kreider,
Director -
Vivo Family Limited Partner...,
10% owner -
William J Motto,
Chairman, CEO -
Antonio Interno,
Senior Vice President -
John A Kraeutler,
Chairman and CEO -
Tony Serafini Lamanna,
Executive VP-Diagnostics